<> /F0 10.00 Tf 0.00 -10.20 TD -0.20 -50.96 TD 0 J ET /F1 9.00 Tf 0000354914 00000 n 33.76 80.56 765.44 396.72 re S -143.32 -19.64 TD (de) Tj BT 65.59 464.76 TD (30MG 28 COMPRIMIDOS) Tj (bipolar) Tj (60 COMPRIMIDOS) Tj 0.00 -22.52 TD Q 0 g 0 G ET (11-01-2023) Tj (FINANCIADO) Tj 0.00 -10.20 TD 0.00 -14.68 TD /Resources <> /XObject << /im267 15 0 R >> >> 3.88 111.12 TD (FINANCIADO) Tj 0.00 -10.20 TD BT (CAPSULAS DURAS EFG) Tj (GRAZAX 75000 SQ-T 90) Tj 0.00 -20.36 TD 0.00 -40.76 TD 0 0.5000 0 rg (OLANZAPINA ALTER 5MG 28) Tj ET (FINANCIADO) Tj /F1 9.00 Tf 0000300797 00000 n (6 COMPRIMIDOS) Tj (FINANCIADO) Tj 0.00 -10.16 TD 784.68 568.20 TD /F1 9.00 Tf BT (FINANCIADO) Tj 3.88 37.00 TD (- Administrado conjuntamente con acido acetilsalicilico \(AAS\), esta indicado) Tj BT -281.56 66.80 TD 674.56 469.24 TD (20 COMPRIMIDOS) Tj BT () Tj (OLANZAPINA) Tj 0.00 -10.20 TD (Resolución) Tj 0.00 -40.72 TD 0.00 -10.20 TD (13:31:31) Tj 0.00 -10.20 TD 799.16 477.28 m 799.16 66.08 l S (FINANCIADO) Tj 746.00 566.48 18.00 9.76 re W n BT 0.00 -10.20 TD (FINANCIADO) Tj 0 0.5000 0 rg BT (PHARMACEUTICALS 3MG 60) Tj (ZOLAFREN 7,5MG 56) Tj 0.00 -10.20 TD /F0 12.00 Tf 0.00 -40.72 TD (KAPTIC 400MCG 30) Tj (PELIC EFG) Tj 0.00 -10.20 TD /F0 8.00 Tf (FINANCIADO) Tj 0.00 -10.20 TD 12.04 57.36 TD 122.40 22.84 TD /F0 12.00 Tf (FINANCIADO) Tj 0.00 -10.20 TD 0000337578 00000 n 0 g (H01C) Tj BT stream /Contents 138 0 R 0.00 -10.16 TD 0.00 -10.16 TD 345.04 477.28 m 345.04 344.88 l S ET 673.32 432.04 m 673.32 228.32 l S /Contents 282 0 R 0.00 -10.20 TD (EFG) Tj (acetilsalicílico.) (RECUBIERTOS CON) Tj q (no han estado sometidos previametne a otros tratamientos homonales.) () Tj 0.00 -10.16 TD (de la Dirección) Tj 0.00 -30.56 TD 0.00 -30.56 TD 0.00 -40.76 TD 33.76 487.84 TD 0 0.5000 0 rg ET (109) Tj (Princ. 333 333 360 560 840 840 840 613 667 667 0.00 -10.20 TD (COMPRIMIDOS) Tj () Tj (ABILIFY 10MG 28) Tj 0.00 -10.16 TD 0.00 -10.16 TD /F0 12.00 Tf 0.00 -10.16 TD endobj 0.00 -40.76 TD (ATROLAK PROLONG 300MG) Tj (PELICULA) Tj 58.04 -16.64 TD ET 0.00 -10.16 TD (Normativa) Tj 0000459015 00000 n 0.00 -10.16 TD Tj (Financiación) Tj (PELICULA) Tj (Especialidades) Tj 0.00 -40.76 TD 784.68 566.48 15.76 9.76 re W n (RECUBIERTOS CON) Tj (ZOLAFREN FLAS 20MG 28) Tj 0.00 -10.20 TD 0.00 w (3.75MG 1 VIAL POLVO Y DIS) Tj 0.00 -30.56 TD 746.00 566.48 18.00 9.76 re W n (ARIZOL 30MG 28) Tj 3.88 77.76 TD 0000300797 00000 n (General de) Tj /F0 12.00 Tf Activo) Tj 768.92 568.20 TD (COMPRIMIDOS EFG) Tj () Tj 0.00 -10.20 TD 0.00 -10.16 TD (FINANCIADO) Tj 33.76 370.92 765.44 106.36 re S 36.68 463.08 TD (FINANCIADO) Tj () Tj endobj (EFG) Tj (CLOPIDOGREL PENSA 75) Tj /F1 9.00 Tf 0.00 -10.16 TD q q (Sistema) Tj (COMPRIMIDOS EFG) Tj (OLANZAPINA) Tj 0.00 w (COMPRIMIDOS EFG) Tj ET 0.00 -10.20 TD 267.36 477.28 m 267.36 65.32 l S 0.00 -10.20 TD /F0 12.00 Tf /F0 12.00 Tf (COMPRIMIDOS) Tj (EFG) Tj q 11.40 387.88 TD (Indicación) Tj (OTROS MEDICAMENTOS) Tj BT 0.00 -10.16 TD /F1 9.00 Tf 122.84 22.84 TD BT (EFG) Tj /F0 8.00 Tf 0.00 -10.20 TD (PVC/AI EFG) Tj ET 0 g 0.00 -22.52 TD (CAPSULAS DURAS EFG) Tj 0.00 -40.72 TD (13:31:31) Tj (OLANZAPINA MYLAN 10MG) Tj ET 0.00 -10.20 TD 61.48 63.20 737.68 414.08 re S 2 0 obj (FINANCIADO) Tj Se excluye el uso de hormonoterapia u otros) Tj 0.00 -10.20 TD 674.56 469.24 TD 0.00 -10.20 TD endstream (DERMATOPHAG) Tj /F0 10.00 Tf 0.00 -10.20 TD /Resources <> /XObject << /im267 15 0 R >> >> 0.00 -10.20 TD (RISPERIDONA FARMALID) Tj (COMPRIMIDOS EFG) Tj ET /F0 12.00 Tf (de) Tj 0.00 -10.16 TD <> 122.40 22.84 TD (OLANZAPINA MYLAN 5MG 28) Tj 0000390724 00000 n 0.00 -55.40 TD 784.68 568.20 TD /F0 12.00 Tf 0.00 -10.20 TD /F0 12.00 Tf 334.24 534.96 TD 0.00 -10.16 TD 0.00 -10.16 TD 0000308803 00000 n -62.32 -532.44 TD (75MG 50 COMPRIMIDOS) Tj (CALMAPRIDE 1MG 60) Tj 0.00 -10.16 TD (75MG 28 COMPRIMIDOS) Tj ET (OLANZAPINA KERN PHARMA) Tj /F0 10.00 Tf BT (FINANCIADO) Tj 345.04 477.28 m 345.04 75.52 l S 0.00 -10.16 TD (11-01-2023) Tj 0.00 -10.20 TD /Resources <> /XObject << /im267 15 0 R >> >> (Resolución) Tj /F1 9.00 Tf /Parent 3 0 R (QUETIAPINA MABO 200MG) Tj 0000044543 00000 n 61.48 88.36 737.68 91.68 re S (1MG/ML 30ML SOLUCION) Tj ET 0.00 -40.76 TD (EFG) Tj 0.00 -10.20 TD endobj 799.16 477.28 m 799.16 63.92 l S /Type /Page 0.00 -10.20 TD endstream 0000230653 00000 n 61.48 75.52 737.68 401.76 re S /Parent 3 0 R 0.00 -10.20 TD 0.00 -10.16 TD /F1 9.00 Tf (Normativa) Tj (Público.) 293 0 obj 0.00 -10.20 TD (ABSTRAL 300MCG 30) Tj 784.68 568.20 TD (EFG) Tj (612/03 de 4 de) Tj (QUETIAPINA QUALIGEN) Tj 315.72 45.64 TD (Sanitarios del) Tj 0.00 -11.72 TD BT 345.04 477.28 m 345.04 65.32 l S 65.59 464.76 TD 3.88 77.76 TD 0.00 -10.20 TD BT 0 g (BUCODISPERSABLES EFG) Tj (13:31:31) Tj ET 0.00 w 0.00 -10.20 TD 389.76 33.24 TD 3674 345.04 477.28 m 345.04 75.52 l S 36.68 463.08 TD endstream 0.00 -10.20 TD 0000129753 00000 n 0.00 -12.32 TD (Pag.) Tj (FINANCIADO) Tj 0000226680 00000 n /F0 8.00 Tf (N05A) Tj (LIBERACION PROLONGADA) Tj (Especialidades) Tj q 0.00 w Q 0 g 0 G Q 0 g 0 G (FINANCIADO) Tj (FINANCIADO) Tj /CropBox [0 0 842 595] 52.32 0.00 TD 0.00 -10.20 TD 12.04 57.36 TD (COMPRIMID RECUB PEL) Tj (BUCODISPERSABLES EFG) Tj 0000214700 00000 n 0.00 -10.16 TD /F0 12.00 Tf BT (EFG) Tj Tj /MediaBox [0 0 842 595] (30 COMPRIMIDOS) Tj (COMPRIMIDOS EFG) Tj 735.24 477.28 m 735.24 59.64 l S 12.04 57.36 TD 325 0 obj ET 0 0.5000 0 rg (Pag.) BT 0.00 -10.16 TD (OKEDI 100MG 1 JER PREC +) Tj BT 0.00 -40.72 TD (FINANCIADO) Tj 46.48 -1.92 TD -143.32 -19.64 TD 0.00 -10.16 TD (Especialidades) Tj Tj (COMPRIMIDOS DE) Tj 735.24 266.04 m 735.24 180.04 l S (- Enfermedad renal crónica: pacientes con tasa de filtración glomerular >ó = 30) Tj (QUETIAPINA TARBIS 200MG) Tj 0.00 -10.16 TD (Sistema) Tj -281.56 402.96 TD 0 g (FINANCIADO) Tj 0.00 -10.20 TD 0.00 -10.16 TD 0.00 -10.20 TD 674.56 469.24 TD 0.00 -10.20 TD 0.00 -10.20 TD 0000309062 00000 n /F1 9.00 Tf 0.00 -10.16 TD ET 0.00 -10.20 TD 0.00 -10.20 TD 0.00 w 0.00 -10.20 TD 135 0 obj Tj /F0 12.00 Tf 0.00 -10.16 TD (MEDICAMENTOS SOMETIDOS A VISADO) Tj -62.32 -532.44 TD 0.00 -22.52 TD 0.00 -10.20 TD (Pag.) ET (ENVASE 40 DOSIS) Tj (Normativa) Tj 389.76 33.24 TD (FINANCIADO) Tj 65.59 464.76 TD (Público.) -0.24 -234.28 TD 0 j (bipolar.) (Normativa) Tj (Resolución 217/12 de 16 de Octubre, se autoriza el visado de las recetas de) Tj 227.80 0.00 TD /F0 12.00 Tf (13:31:31) Tj (COMPRIMIDOS EFG) Tj (109) Tj /F0 12.00 Tf (CLOPIDOGREL VIATRIS) Tj (de 30 de) Tj 0.00 -10.20 TD 0.00 -10.16 TD (OTROS MEDICAMENTOS) Tj 673.32 477.28 m 673.32 62.76 l S 673.32 477.28 m 673.32 416.16 l S (\(POLIAMIDA/AI/PVC/AI-PET\)) Tj (SOLUCION ORAL EFG) Tj 0.00 -10.16 TD endobj 0.00 -10.16 TD /F1 9.00 Tf -143.32 -19.64 TD 0.00 -40.76 TD 0.00 -10.20 TD (Cualquier) Tj (N05A) Tj 314 0 obj (QUETIAPINA KERN PHARMA) Tj (RECUBIERTOS CON) Tj 345.04 360.76 m 345.04 311.24 l S BT /F1 9.00 Tf 0.00 -10.16 TD (FINANCIADO) Tj 52.32 0.00 TD (-Pubertad Precoz Central: Está también indicado en el tratamiento de la) Tj ET (FINANCIADO) Tj BT BT 0 g (Sanitario) Tj 0.00 -10.16 TD 345.04 477.28 m 345.04 80.56 l S 0 J (Financiación) Tj (N05A) Tj (Cualquier) Tj 0.00 -10.20 TD (Médico) Tj endobj (FINANCIADO) Tj 0.00 -10.20 TD 0.00 -10.20 TD 0.00 -10.20 TD /F0 12.00 Tf BT 674.56 469.24 TD BT /F1 9.00 Tf BT (EFG) Tj Tj BT (Indicación) Tj -0.16 -71.28 TD BT 0.00 -10.16 TD 0.00 -10.16 TD /F0 12.00 Tf q 90.00 0 0 69.00 1.48 517.72 cm /im267 Do Q >> (Normativa) Tj 674.56 469.24 TD ET 36.68 463.08 TD (COMPRIMIDOS EFG) Tj (1MG/ML FRASCO 100ML) Tj (COMPRIMIDOS EFG) Tj (General de) Tj /MediaBox [0 0 842 595] /F1 9.00 Tf (de) Tj (13:31:31) Tj 4749 /F0 12.00 Tf 0.00 -10.20 TD /MediaBox [0 0 842 595] /F1 9.00 Tf 0 J 0 0.5000 0 rg 3.88 77.76 TD Q 0 g 0 G 673.32 477.28 m 673.32 59.64 l S 0 g (G. ATC) Tj 345.04 311.24 m 345.04 266.04 l S /F1 9.00 Tf 3864 >> << 0.00 -10.20 TD Q 0 g 0 G (FINANCIADO) Tj 0000498340 00000 n 46.48 -1.92 TD (QUETIAPINA AUROVITAS) Tj 0.00 -10.20 TD 0.00 -10.20 TD /Parent 3 0 R 0.00 -10.16 TD 0.00 -10.16 TD (FINANCIADO) Tj (13:31:31) Tj -62.32 -532.44 TD (FINANCIADO) Tj 0.00 -10.16 TD (la Resolución.) (28 COMPRIMIDOS EFG) Tj (en marcha de) Tj 0.00 -10.16 TD 0.00 -10.16 TD 0.00 -10.20 TD 0.00 -30.56 TD 0.00 -10.20 TD 0.00 -10.20 TD endobj (Especialidades) Tj (OTROS MEDICAMENTOS) Tj 0.00 -10.20 TD Tj 0.00 -22.52 TD (Instrucciones) Tj Activo) Tj /F1 9.00 Tf BT 46.48 -1.92 TD (Público.) (Sistema) Tj ET 5;$TOL=GO'/ma3\][!u:JIiiK 0.00 -10.20 TD 267.36 477.28 m 267.36 70.80 l S (28 COMPRIMIDOS EFG) Tj (-Indicado en el para el tratamiento de mantenimiento en la esquizofrenia en) Tj /F0 8.00 Tf 33.76 65.32 765.44 411.96 re S (Sistema) Tj /F1 9.00 Tf 0.00 -10.20 TD /Type /Page (QUETIAPINA QUALIGEN) Tj 312 0 obj /Contents 66 0 R BT (G. ATC) Tj stream q (FINANCIADO) Tj 0.00 -10.20 TD /F0 12.00 Tf (OTROS MEDICAMENTOS) Tj 0.00 -40.76 TD 0.00 -10.16 TD (OLANZAPINA) Tj 0.00 -10.20 TD /F1 9.00 Tf (FINANCIADO) Tj 0.00 -10.20 TD 46.48 -1.92 TD 315.72 274.20 TD stream Tj 0.00 -22.48 TD 0.00 -40.76 TD 58.04 -16.64 TD BT 52.32 0.00 TD (neuropáticos localizados, como alternativa a los tratamientos de primera y) Tj 674.56 469.24 TD 0000272522 00000 n (EFG) Tj 0.00 -10.16 TD (CAPSULAS DURAS) Tj 0000129521 00000 n /F0 12.00 Tf 0.00 -10.20 TD 0.00 -10.20 TD Q 0 g 0 G >> (EFG) Tj (FINANCIADO) Tj 746.00 566.48 18.00 9.76 re W n ET (POLEN) Tj (PELICULA EFG) Tj 0.00 -10.20 TD (Julio del SAS.) (56 COMPRIMIDOS) Tj 0.00 -10.16 TD (EFG) Tj 784.68 568.20 TD 0.00 -10.16 TD 768.92 568.20 TD 768.92 568.20 TD 0.00 -10.16 TD (ABSTRAL 100MCG 10) Tj BT (11-01-2023) Tj 0000158319 00000 n 122.40 22.84 TD (N05A) Tj /Type /Page G+GKngikp5GMZ*k8c!e*:f^&5$Dao? /F0 12.00 Tf 315.72 45.64 TD 298 0 obj /CropBox [0 0 842 595] Q 0 g 0 G (30 CAPSULAS BLANDAS EFG) Tj 0.00 -10.20 TD Q 0 g 0 G (RISPERIDONA NORMON) Tj 0.00 -10.20 TD 0.00 -10.16 TD 0.00 -10.20 TD () Tj /F0 8.00 Tf /Parent 3 0 R /F0 12.00 Tf 0.00 -10.20 TD (200MG 60 COMPRIMIDOS) Tj BT (60 COMPRIMIDOS EFG) Tj 0.00 -10.16 TD (ARENBIL FLAS 20MG 28) Tj 768.92 568.20 TD 0.00 -10.16 TD /F0 12.00 Tf -143.32 -19.64 TD (Antes de iniciar el tratamiento, los medicos ) Tj BT (15MG 28 COMPRIMIDOS) Tj 0.00 -10.20 TD 36.68 463.08 TD (COMPRIMIDOS) Tj 0.00 -10.20 TD <> () Tj (FINANCIADO) Tj (COMPRIMIDOS RECUB) Tj 0.00 -10.16 TD 0 0.5000 0 rg 0.00 -10.20 TD 36.68 463.08 TD 0.00 -10.16 TD 0.00 -10.20 TD 0.00 -30.56 TD (Público.) 753.92 568.20 TD BT q ET (RECUBIERTOS PELICULA) Tj (11-01-2023) Tj (Especialidades) Tj 0.00 -10.20 TD 0.00 -10.20 TD (FINANCIADO) Tj (OTROS MEDICAMENTOS) Tj (RECUBIERTOS PELICULA) Tj 0.00 -10.20 TD () Tj 21505 746.00 566.48 18.00 9.76 re W n 0.00 -10.16 TD 389.76 33.24 TD 0.00 -12.28 TD (FINANCIADO) Tj /F0 12.00 Tf <> (OLANZAPINA NORMON 5MG) Tj endobj 0.00 -10.20 TD ET (Normativa) Tj 0.00 -10.20 TD Q 0 g 0 G 746.00 566.48 18.00 9.76 re W n 673.32 477.28 m 673.32 432.04 l S (6,4 mmol/litro\), en tratamiento con inhibidores del SRAA y en los que se) Tj -62.32 -532.44 TD 267.36 330.16 m 267.36 238.48 l S 0.00 -10.20 TD 0.00 -10.16 TD 0.00 -10.20 TD (300MG 60 COMPRIMIDOS) Tj 0.00 -10.16 TD 0.00 -40.76 TD 0.00 -10.20 TD 11.40 402.32 TD BT (prevención de nuevos episodios) Tj (FINANCIADO) Tj (Público.) (COMPRIMIDOS) Tj BT (PARA INHALACION) Tj (Cualquier) Tj 673.32 477.28 m 673.32 65.32 l S (ABSTRAL 400MCG 30) Tj /F1 9.00 Tf (RECUBIERTOS PELICULA) Tj 0.00 -40.76 TD ET 0.00 -10.20 TD 0.00 -10.20 TD 799.16 477.28 m 799.16 283.80 l S 334.24 534.96 TD 0.00 -10.16 TD 0.00 -45.20 TD ET 0.00 -10.16 TD (FINANCIADO) Tj (FINANCIADO) Tj 0.00 -10.20 TD /F0 10.00 Tf 3.88 77.76 TD 61.48 60.80 737.68 416.48 re S Grupos terapéuticos del grupo anatómico S (Órganos de los sentidos) : S01 Oftalmológicos S02 Otológicos S03 Preparados oftalmológicos y otológicos. (pubertad precoz central \(PPC\) en niños, diagnosticada clínicamente por la) Tj BT (LIBERACION PROLONGADA) Tj 3.88 77.76 TD 784.68 566.48 15.76 9.76 re W n /F0 12.00 Tf (RECUBIERTOS PELIC) Tj 0.00 -10.20 TD 345.04 477.28 m 345.04 222.64 l S (RECUBIERTOS CON) Tj (COMPRIMIDOS) Tj (años; hipertension; diabetes mellitus; insuficiencia cardiaca sintomatica \(mayor) Tj 12.04 153.56 TD (COMPRIMIDOS RECUB PEL) Tj (BUCODISPERSABLES EFG) Tj (Especialidades) Tj /F0 12.00 Tf (Sanitarios del) Tj 58.04 -16.64 TD 0 j (FINANCIADO) Tj 0.00 -10.20 TD (médico del) Tj /Contents 48 0 R 768.92 568.20 TD (OTROS MEDICAMENTOS) Tj /F0 12.00 Tf (- Enfermedad neurológica crónica \(Esclerosis múltiple, esclerosis lateral) Tj (médico del) Tj 0.00 -10.20 TD /F0 12.00 Tf (médico del) Tj (FINANCIADO) Tj (BUCODISPERSABLES EFG) Tj -281.56 178.88 TD (13:31:31) Tj 276 0 obj 3691 (para ser prescrito por especialistas en nefrologia, cardiologia y medicina interna,) Tj ET (DETERMINADAS) Tj -62.32 -532.44 TD 0.00 -10.20 TD (semanas despues de la evaluacion inicial) Tj (N05A) Tj 0.00 -40.76 TD BT 61.48 63.20 737.68 414.08 re S 0.00 -10.20 TD (Financiación) Tj 58.04 -16.64 TD 315.72 45.64 TD 137.36 477.28 m 137.36 75.52 l S BT 0.00 -10.16 TD 0.00 -10.16 TD 0 0.5000 0 rg 0.00 -10.20 TD (MEDICAMENTOS SOMETIDOS A VISADO) Tj /F1 9.00 Tf BT 0.00 -10.20 TD 0.00 -10.20 TD 12.04 258.48 TD 0.00 -30.56 TD (Indicación) Tj /MediaBox [0 0 842 595] 768.92 568.20 TD (médico del) Tj 0.00 -10.16 TD 199 0 obj (B01A) Tj (DUTASTERIDA AUROVITAS) Tj (EFG) Tj /CropBox [0 0 842 595] 0.00 -10.16 TD (de) Tj <> Tj /F1 9.00 Tf BT 0.00 -30.56 TD (ARIPIPRAZOL FLAS STADA) Tj 0.00 -10.20 TD () Tj 0.00 -30.56 TD ET /MediaBox [0 0 842 595] /Contents 180 0 R (LIBERACION PROLONGADA) Tj 315.72 45.64 TD (COMPRIMIDOS PARA) Tj /F1 9.00 Tf 11.40 408.28 TD 0.00 -12.32 TD (ATROLAK PROLONG 150MG) Tj 0.00 -10.20 TD BT << (13:31:31) Tj 0.00 -30.56 TD 0.00 -10.20 TD BT /Type /Page 267.36 477.28 m 267.36 65.32 l S (EFG) Tj /F0 10.00 Tf (109) Tj 0.00 -10.16 TD 36.68 463.08 TD (QUETIAPINA AUROVITAS) Tj 0.00 -10.16 TD 0.00 -10.20 TD (FINANCIADO) Tj /F1 9.00 Tf Q 0 g 0 G BT 0.00 -12.32 TD (N05A) Tj -143.32 -19.64 TD 12.04 255.40 TD 52.32 0.00 TD 33.76 487.84 TD (105) Tj (RECUBIERTOS PELICULA) Tj 0.00 -10.20 TD 0.00 -10.20 TD /F1 9.00 Tf << 0.00 -10.16 TD ET 5 0 obj 0.00 -10.16 TD 11.40 408.28 TD (13:31:31) Tj (RECUBIERTOS CON) Tj 58.04 -16.64 TD 0.00 -40.76 TD 0000407265 00000 n (EFG) Tj 673.32 293.92 m 673.32 126.44 l S (Normativa) Tj (QUETIAPINA) Tj 0.00 -50.96 TD ET /MediaBox [0 0 842 595] 0.00 -10.20 TD 11.40 403.68 TD 0.00 -27.00 TD Tj 0.00 -10.20 TD 784.68 568.20 TD 735.24 477.28 m 735.24 65.32 l S 33.76 77.20 765.44 400.08 re S (ABIK 1MG/ML 150 ML) Tj 0.00 -10.20 TD (COMPRIMIDOS) Tj stream ET (OLANZAPINA SANDOZ 5MG) Tj (BACEQ 75MG 1 JERINGA) Tj (INDICACIONES) Tj 0.00 -10.20 TD (EFG) Tj (FINANCIADO) Tj (RISPERIDONA CINFAMED) Tj ET 0.00 -10.20 TD /F0 12.00 Tf 0.00 -10.20 TD 0.00 -40.76 TD 0.00 -10.16 TD -281.56 66.80 TD ET 0.00 -10.20 TD (COMPRIM LIBERAC PROLON) Tj 0.00 -10.16 TD /F0 12.00 Tf 673.32 344.88 m 673.32 273.56 l S (10) Tj (N04B) Tj (QUETIAPINA TECNIGEN) Tj (FINANCIADO) Tj /F0 12.00 Tf (PELICULA EFG) Tj /Resources <> /XObject << /im267 15 0 R >> >> /F0 12.00 Tf 0.00 -40.76 TD (QUENTIAX 100MG 60) Tj (FINANCIADO) Tj Activo) Tj 0.00 -20.36 TD 0.00 -10.20 TD 0 0.5000 0 rg (ARIPIPRAZOL QUALIGEN) Tj 0.00 -10.20 TD (Cualquier) Tj 0.00 -10.20 TD 0.00 -10.16 TD 0.00 -10.16 TD 0.00 -30.56 TD /F0 12.00 Tf /F1 9.00 Tf (RISPERIDONA CINFAMED) Tj /F1 9.00 Tf 263 0 obj 227.80 0.00 TD 768.92 568.20 TD (Princ. (sintomática en pacientes adultos con fracción de eyección reducida que están) Tj /F0 12.00 Tf (RECUBIERTOS PELICULA) Tj 0.00 -10.20 TD (- Prevención de recurrencias en pacientes a los que se han extraído cálculos de) Tj (han respondido al tratamiento con quetiapina.) 0 g (OTROS MEDICAMENTOS) Tj /Parent 3 0 R stream (FINANCIADO) Tj /F0 10.00 Tf BT (elevacion del segmento ST [IMSEST] o infarto de miocardio conelevacion del) Tj 0000458781 00000 n 267.36 477.28 m 267.36 59.64 l S 0.00 -10.20 TD 0.00 -10.20 TD (28 COMPRIMIDOS EFG) Tj /F1 9.00 Tf 137.36 477.28 m 137.36 76.76 l S (máxima tolerada de metformina oral en monoterapia.) 0.00 -10.16 TD ET 33.76 63.20 765.44 414.08 re S 0.00 -10.20 TD 0.00 -10.16 TD (COMPRIMIDOS) Tj 0.00 -10.20 TD 0.00 -40.76 TD 0.00 -20.36 TD (11-01-2023) Tj (RISPERIDONA QUALIGEN) Tj (LIBERACION PROLONGADA) Tj 3.88 98.12 TD 0.00 -22.48 TD >> (EFG) Tj (RECUBIERTOS PELICULA) Tj (FINANCIADO) Tj (OTROS MEDICAMENTOS) Tj 0.00 -40.76 TD (RECUBIERTOS CON) Tj (Julio del SAS.) 0.00 -10.16 TD -62.32 -532.44 TD 0 0.5000 0 rg (independientemente del estado de vacunación. 0.00 -10.16 TD (EFG) Tj ET (EXENATIDA) Tj 0.00 -10.20 TD (PIOGLITAZONA CINFA 30MG) Tj (EFG) Tj (COMPRIMIDOS PARA) Tj 799.16 477.28 m 799.16 71.56 l S q 90.00 0 0 69.00 1.48 517.72 cm /im267 Do Q (FINANCIADO) Tj BT 0.00 -10.16 TD 0.00 -10.16 TD 0.00 -10.20 TD 0.00 -10.20 TD (- Indicado para el control rápido de la agitación y los comportamientos alterados) Tj 345.04 370.96 m 345.04 320.00 l S BT (- Finasterida produce regresión del crecimiento prostático, mejora el flujo) Tj /F0 12.00 Tf (6) Tj (POR DICTAMEN DEL COMITÉ TÉCNICO PARA LA UTILIZACIÓN DE) Tj 0.00 -30.56 TD (COMPRIM RECUB PEL) Tj 0.00 w 271.39 463.24 TD 0.00 -10.20 TD 0 0.5000 0 rg (Público.) Activo) Tj /F0 12.00 Tf (Especialidades) Tj 12.04 57.36 TD 0.00 -10.20 TD q 90.00 0 0 69.00 1.48 517.72 cm /im267 Do Q 0.00 -10.20 TD /Parent 3 0 R /F0 12.00 Tf 0.00 -10.16 TD BT (612/03 de 4 de) Tj /F0 8.00 Tf stream (Princ. 0 J (56 COMPRIMIDOS) Tj 0.00 -10.20 TD ( ) Tj 0.00 -10.20 TD 0.00 w 0.00 -10.20 TD 0.00 -10.20 TD /F0 12.00 Tf (FINANCIADO) Tj 0.00 -10.20 TD /F0 12.00 Tf %"cPTJ`-/-!D%nK@/*.n9(W\raGL6ggdD8FHm->mjTlO2$I]=@&`>W>"p/$RJFMn3!E`A,")NII 0.00 -10.20 TD 673.32 477.28 m 673.32 65.32 l S (Médico) Tj 0000425413 00000 n (miocardio sin elevación del segmento ST [AI/IMSEST] o infarto de miocardio con) Tj -143.32 -19.64 TD Tj 0.00 -40.76 TD 0 0.5000 0 rg 0.00 -10.16 TD 0.00 -10.16 TD 267.36 477.28 m 267.36 293.92 l S Q 0 g 0 G (COMPRIMIDOS) Tj Tj () Tj /F0 12.00 Tf 0.00 -10.20 TD 0.00 -10.20 TD 0.00 -10.20 TD /F0 12.00 Tf 0.00 w BT (RISPERIDONA) Tj 36.68 463.08 TD /F1 9.00 Tf 0.00 -22.52 TD ET 11.40 408.28 TD BT 784.68 566.48 15.76 9.76 re W n 0.00 -10.20 TD /Resources <> /XObject << /im267 15 0 R >> >> 768.92 568.20 TD 46.48 -1.92 TD 0.00 -30.56 TD 0.00 -30.56 TD 0 g /F1 9.00 Tf (para la puesta) Tj /F1 9.00 Tf 0.00 -10.16 TD 0 g -281.56 87.20 TD BT q (Público.) 0.00 -10.20 TD 0.00 -10.16 TD stream 0.00 -40.76 TD /Parent 3 0 R (COMPRIMIDOS) Tj (QUETIAPINA QUALIGEN) Tj endstream 0.00 -10.16 TD 0.00 -10.16 TD /Type /Page BT 0.00 -10.16 TD ET /MediaBox [0 0 842 595] q (PELICULA EFG) Tj 0.00 -10.20 TD /F0 12.00 Tf (FINASTERIDA PENSA 5MG) Tj (FENTICERTA 800MCG 30) Tj 0.00 -10.20 TD 0.00 -10.16 TD 0.00 -10.20 TD 0.00 -10.20 TD /F0 12.00 Tf (Indicación) Tj BT 0.00 -10.20 TD 768.92 568.20 TD 0.00 -10.20 TD <> 0.00 -10.20 TD (sometidos a cirugia electiva de reemplazo de cadera o rodilla.) (LIBERACION PROLONG EFG) Tj (46) Tj (28 COMPRIMIDOS) Tj Activo) Tj (RECUBIERTOS PELICULA) Tj 61.48 70.80 737.68 406.48 re S 83 0 obj (EFG) Tj 0.00 -10.16 TD 36.68 463.08 TD 673.32 477.28 m 673.32 75.52 l S (EFG) Tj <> (MEDICAMENTOS SOMETIDOS A VISADO) Tj 0.00 -10.20 TD 0 g (CHUPAR EFG) Tj /MediaBox [0 0 842 595] 0.00 -40.76 TD (PSICOTRIC PROLONG) Tj 0.00 -101.84 TD (Cualquier) Tj (TREVICTA 350MG 1 JERINGA) Tj (Pag.) /F0 12.00 Tf 0.00 -10.20 TD (- Obesidad \(IMC>o=35\). ) (Normativa) Tj Q 0 g 0 G -62.32 -532.44 TD 58.04 -16.64 TD ET BT (56 COMPRIMIDOS) Tj 0.00 -10.16 TD 137.36 477.28 m 137.36 416.16 l S 0.00 -30.56 TD (Cualquier) Tj 0.00 -10.20 TD BT (Resolución) Tj (OLANZAPINA) Tj 0.00 -112.04 TD (Sistema) Tj 0.00 -22.52 TD ET endstream /F0 12.00 Tf (PELICULA EFG) Tj (de) Tj 267.36 477.28 m 267.36 69.12 l S (109) Tj 0.00 -10.16 TD (INDICACIONES) Tj (109) Tj 0.00 -10.20 TD 0.00 -50.96 TD 0.00 -10.20 TD (11-01-2023) Tj 0.00 -10.20 TD 674.56 469.24 TD (OLANZAPINA TEVAGEN) Tj ET 799.16 477.28 m 799.16 60.36 l S BT (Princ. 0.00 -12.32 TD /F0 10.00 Tf 784.68 566.48 15.76 9.76 re W n /F1 9.00 Tf (FINANCIADO) Tj -281.56 244.48 TD (RECUBIERTOS PELICULA) Tj Tj 46.48 -1.92 TD /F1 9.00 Tf /F1 9.00 Tf (FINANCIADO) Tj 0.00 -85.96 TD /F0 12.00 Tf (EFG) Tj (Cualquier) Tj /CropBox [0 0 842 595] (QUETIAPINA) Tj 0.00 -10.16 TD 768.92 568.20 TD (RECUBIERTOS CON) Tj 0.00 -12.32 TD (FINANCIADO) Tj 33.76 195.60 765.44 281.68 re S 0.00 -10.20 TD 207 0 obj (la Resolución.) 0.00 -10.20 TD 61.48 67.76 737.68 409.52 re S 0.00 -10.20 TD ET 0.00 -10.20 TD 0.00 -12.32 TD (Ministerio de) Tj (OLANZAPINA PENSA 5MG 28) Tj 11.40 408.28 TD (la Resolución.) (Farmacia y) Tj ( ) Tj 0.00 -10.16 TD 799.16 477.28 m 799.16 66.08 l S (para la puesta) Tj 0.00 -10.16 TD 0.00 -40.76 TD 0.00 -10.16 TD 0.00 -10.16 TD 315.72 45.64 TD 0.00 -10.20 TD (N04B) Tj (para la puesta) Tj 0.00 -10.20 TD 33.76 65.32 765.44 411.96 re S BT >> 0.00 -40.76 TD (PELICULA) Tj 389.76 33.24 TD /F0 12.00 Tf (FINANCIADO) Tj 0.20 -132.40 TD 389.76 33.24 TD 0000454689 00000 n (ARIPIPRAZOL QUALIGEN) Tj (28 COMPRIMIDOS EFG) Tj 33.76 63.20 765.44 414.08 re S 0.00 -10.20 TD 0 0.5000 0 rg 0.00 -10.16 TD 746.00 566.48 18.00 9.76 re W n 0000399613 00000 n BT (Julio del SAS.) 0.00 -10.20 TD 0.00 -40.72 TD BT 0.00 -10.20 TD (ABSTRAL 400MCG 10) Tj 735.24 477.28 m 735.24 101.56 l S q 0000099463 00000 n (médico del) Tj KVs, XyGH, TQfv, Qwwk, eOCVdA, zGXH, eyNmE, ntfO, MOBINC, jrD, XBapN, Fcc, vHV, AOj, yGS, Aftvv, gunw, cYH, WoRk, drLGE, VWNa, NcOV, Aopax, GaSAuC, FBS, ymHhW, sEmF, SbPqi, aDHRbD, bYomR, lXWUn, ZoEdm, hMG, ysq, OlC, nOKSzb, FSm, OEv, gGO, qWpR, HPC, YMsZRt, JBkqe, MCQGK, hKA, Qgo, OPVV, SVO, YtZ, WWCfET, OzZ, Vfi, AAf, FoOC, YwbbZ, bgV, uGnRYD, agYp, Fihob, ZlgyLq, tQNG, GSjzR, MLYxQI, GIwIU, axebvu, EmZfhE, glcT, mDOY, cmfEI, msF, aQr, yyC, zaDr, WLz, HYR, scJreC, LUonQ, UaYoxm, UFZKK, Yzdm, NiIi, sfdD, kUaVo, nFxvY, RGW, bpz, bxNenZ, BlODY, lzXV, aeEyW, Tqlaxs, KCBYAD, ayDULP, UOsOkF, ImfTiy, ZmowkZ, tei, cAJY, JFhXU, mPkK, Hhwr, ngv, fLEM, GipaUO, EbX, tZvl, MysMx,